Preface

This book provides updated information on immune checkpoint inhibitors and their role in disease dynamics, especially in cancers. The chapters discuss the mechanisms of action of immune checkpoint inhibitors, the role of novel immune checkpoint inhibitors in therapeutics/immune-related adverse events, and immune checkpoint inhibitors as predictors of response. Furthermore, the chapters also focus on current clinical trials being carried out on several novel immune checkpoint molecules and their utility in therapeutics, overall response rates, and survival. The book delves into critical topics such as the advances and challenges of immune checkpoint molecules with respect to their use in clinical practice. The insights from this book serve as a foundation for preclinical and clinical studies to identify unexplored pathways that need attention at a global scale to improve the role of immune checkpoint inhibitors in cancers.
